HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm

Hims & Hers shares fell $4.32, or 14.73%, to $25.00 on July 29, 2026, after the FTC sued the company over alleged sharing of customers’ medical information with third-party advertisers. A securities fraud class action alleges HIMS made misleading statements and omitted disclosures about its privacy practices, prescription charges, and potential regulatory scrutiny; investors have until November 2, 2026, to seek lead-plaintiff status.

Analysis

The class-action notice adds little incremental information: it is a follow-on to the FTC action, and the allegations remain unproven. The investment question is whether privacy and consent practices force Hims & Hers Health, Inc. (HIMS) to change customer acquisition, intake, or billing flows. If those changes reduce conversion or increase customer-acquisition costs, the impact could persist beyond any eventual legal payment; a settlement alone may be less important than an operating-model constraint. The July selloff may already reflect some headline risk, while the November 2 lead-plaintiff deadline is procedural rather than a near-term fundamental catalyst.

Over the next 1–3 months, monitor FTC filings and requested remedies, HIMS disclosures, and evidence of changes to advertising attribution, intake conversion, retention, or marketing spend. Over 6–18 months, broader privacy enforcement could raise compliance costs across digital health and constrain targeted advertising. Snap Inc. and Meta Platforms, Inc. are named as alleged recipients of information, but the notice does not establish they are defendants or face material company-specific liability; their exposure here is primarily precedent and tighter data-handling controls. The source is a plaintiff-side law firm announcement, not an independent assessment of damages or likely outcome.

Key Decisions for Investors

• Do not treat the class-action announcement alone as a fresh short catalyst. Keep HIMS underweight pending verification of the FTC case’s scope and any operating changes; the July 29 price decline suggests the initial privacy headline has already been repriced to some extent.
• Consider a relative underweight in HIMS versus a diversified healthcare or consumer-internet exposure only if subsequent filings or company disclosures indicate restrictions that impair customer acquisition or intake conversion. Avoid sizing from the lawsuit notice without current valuation, borrow, and position data.
• Set an alert for FTC remedies, HIMS guidance revisions, and reported customer-acquisition costs, conversion, or retention. Escalate the bearish thesis if operating metrics weaken or the FTC seeks remedies that constrain data use; reduce it if the action is narrowed or dismissed and HIMS demonstrates stable funnel economics.
• Do not infer a direct short in SNAP or META from their mention in the allegations. Reassess only if regulators pursue them directly or evidence indicates material, broader changes to ad-targeting economics.